{"filing":{"accession_number":"0001323885-26-000032","cik":"0001323885","ticker":"ATRC","company_name":"AtriCure, Inc.","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"atrc-20260723.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1323885/000132388526000032/atrc-20260723.htm"},"events":[{"id":19989,"run_id":17997,"accession_number":"0001323885-26-000032","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"AtriCure issued a press release on July 23, 2026 disclosing second quarter 2026 financial results, including revenue of $153.6 million (12.8% YoY growth), net income of $9.0 million, and adjusted EBITDA of $27.3 million. The filing includes condensed consolidated statements of operations and balance sheets, along with full-year 2026 financial guidance. This is a standard quarterly earnings disclosure furnished under Item 2.02.","company_name":"AtriCure, Inc.","ticker":"ATRC","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19234,"accession_number":"0001323885-26-000032","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"AtriCure issued a press release on July 23, 2026 disclosing second quarter 2026 financial results, including revenue of $153.6 million (12.8% YoY growth), net income of $9.0 million, and adjusted EBITDA of $27.3 million. The filing includes condensed consolidated statements of operations and balance sheets, along with full-year 2026 financial guidance. This is a standard quarterly earnings disclosure furnished under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:02:09.354825+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19234,"accession_number":"0001323885-26-000032","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"AtriCure issued a press release on July 23, 2026 disclosing second quarter 2026 financial results, including revenue of $153.6 million (12.8% YoY growth), net income of $9.0 million, and adjusted EBITDA of $27.3 million. The filing includes condensed consolidated statements of operations and balance sheets, along with full-year 2026 financial guidance. This is a standard quarterly earnings disclosure furnished under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:02:09.354825+00:00","company_name":"AtriCure, Inc.","ticker":"ATRC","filing_date":"2026-07-23"}]}